Click on the button under the session details to view the agenda.
Monday
Industry symposium – Novo Nordisk A/S
- Novo Nordisk A/S
- Monday, 28 September 2026
- 09:00 - 18:00 CEST
- Milan Hall
Industry symposium – Eli Lilly and Company
- Eli Lilly and Company
- Monday, 28 September 2026
- 09:00 - 18:00 CEST
- London Hall
Industry symposium – Abott Diabetes Care
- Abott Diabetes Care
- Monday, 28 September 2026
- 10:00 - 11:30 CEST
- Madrid Hall
Rethinking Obesity Management: From Biologic Complexity to Patient-Centered Care
- Amgen, Inc.
- Monday, 28 September 2026
- 11:00 - 12:00 CEST
- Warsaw Hall
Unlocking scalable T1D Autoantibody Testing in Clinical Care
- Sanofi
- Monday, 28 September 2026
- 11:30 - 12:30 CEST
- Sofia Hall
Industry symposium – SIBIONICS
- SIBIONICS
- Monday, 28 September 2026
- 12:00 - 13:00 CEST
- Dublin Hall
Obesity rewired – Live news and views
- Regeneron
- Monday, 28 September 2026
- 12:00 - 13:30 CEST
- Budapest Hall
Industry symposium – Boehringer Ingelheim International GmbH
- Boehringer Ingelheim International GmbH
- Monday, 28 September 2026
- 12:30 - 13:30 CEST
- Berlin Hall
A new era in autoimmune T1D: Translating emerging potential into clinical reality with teplizumab
- Sanofi
- Monday, 28 September 2026
- 13:00 - 14:00 CEST
- Sofia Hall
Non-steroidal MRAs – Expanding Cardiorenal Care in Diabetes and Beyond
- Sciarc GmbH
- Monday, 28 September 2026
- 13:00 - 14:00 CEST
- Madrid Hall
Industry symposium – AstraZeneca
- AstraZeneca
- Monday, 28 September 2026
- 13:00 - 14:30 CEST
- Vienna Hall
Industry symposium – Boehringer Ingelheim International GmbH
- Boehringer Ingelheim International GmbH
- Monday, 28 September 2026
- 13:30 - 15:00 CEST
- Warsaw Hall
Injection Technique in Endocrine Therapy: Addressing Lipohypertrophy and Enhancing Outcomes Across Insulin and GLP-1 Injectables
- embecta
- Monday, 28 September 2026
- 15:00 - 15:30 CEST
- Dublin Hall
Reducing acute pancreatitis through apoC-III inhibition in patients with severe hypertriglyceridemia
- Sobi
- Monday, 28 September 2026
- 15:30 - 16:30 CEST
- Madrid Hall
Tuesday
Hot Topic Session – Eli Lilly and Company
- Eli Lilly and Company
- Tuesday, 29 September 2026
- 11:30 - 12:00 CEST
- Spotlight Stage
Hot Topic Session – Sanofi
- Sanofi
- Tuesday, 29 September 2026
- 14:15 - 14:45 CEST
- Spotlight Stage
Hot Topic Session – Novo Nordisk A/S
- Novo Nordisk A/S
- Tuesday, 29 September 2026
- 16:15 - 16:45 CEST
- Spotlight Stage
Finding, Staging and Managing Early-Stage T1D In the Real World: A Practical Evidence Update for 2026
- Sanofi
- Tuesday, 29 September 2026
- 18:00 - 19:00 CEST
- Madrid Hall
The earlier, the longer, the better in Diabetes management
- Menarini Group
- Tuesday, 29 September 2026
- 18:00 - 19:00 CEST
- Berlin Hall
Industry symposium – Novo Nordisk A/S
- Novo Nordisk A/S
- Tuesday, 29 September 2026
- 18:00 - 19:30 CEST
- Sofia Hall
Industry symposium – Abbott
- Abbott
- Tuesday, 29 September 2026
- 18:15 - 19:15 CEST
- Vienna Hall
Wednesday
Industry symposium – Merck Healthcare KGaA
- Merck Healthcare KGaA
- Wednesday, 30 September 2026
- 07:15 - 08:15 CEST
- Sofia Hall
At the Cutting Edge of Automated Insulin Delivery: CamAPS Liberty, Pregnancy and the Menstrual Cycle
- mylife Diabetes Care
- Wednesday, 30 September 2026
- 07:15 - 08:15 CEST
- Madrid Hall
Industry symposium – Roche
- Roche
- Wednesday, 30 September 2026
- 07:45 - 08:15 CEST
- Berlin Hall
Arena Talk – Boehringer Ingelheim International GmbH
- Boehringer Ingelheim International GmbH
- Wednesday, 30 September 2026
- 07:45 - 08:15 CEST
- Arena
Hot Topic Session – Abbott
- Abbott
- Wednesday, 30 September 2026
- 11:15 - 11:45 CEST
- Spotlight Stage
A new era in autoimmune T1D: Navigating the realities of teplizumab treatment
- Sanofi
- Wednesday, 30 September 2026
- 11:15 - 11:45 CEST
- Arena
Hot Topic Session – Dexcom Inc.
- Dexcom Inc.
- Wednesday, 30 September 2026
- 14:00 - 14:30 CEST
- Spotlight Stage
BR1DGE Talk: Practical Guidance on Optimizing the Sustainability and Cost Effectiveness of T1D Screening
- Sanofi
- Wednesday, 30 September 2026
- 14:00 - 14:30 CEST
- Arena
Hot Topic Session – Eli Lilly and Company
- Eli Lilly and Company
- Wednesday, 30 September 2026
- 16:00 - 16:30 CEST
- Spotlight Stage
A New Direction in T1D? Redefining Success From Survival to Freedom
- Vertex Pharmaceuticals Inc.
- Wednesday, 30 September 2026
- 16:00 - 16:30 CEST
- Arena
Muscle Health in Diabetes: A New Lever to Improve Glycemic Control and Patient Outcomes
- Abbott
- Wednesday, 30 September 2026
- 17:45 - 18:15 CEST
- Arena
Liver-Directed Approach to Moderate to Advanced MASH: Implications for Diabetes Specialists
- Madrigal Pharmaceuticals
- Wednesday, 30 September 2026
- 17:45 - 18:45 CEST
- Berlin Hall
Industry symposium – Novo Nordisk A/S
- Novo Nordisk A/S
- Wednesday, 30 September 2026
- 17:45 - 19:15 CEST
- Sofia Hall
Industry symposium – Eli Lilly and Company
- Eli Lilly and Company
- Wednesday, 30 September 2026
- 17:45 - 18:45 CEST
- Madrid Hall
Thursday
Hot Topic Session – Novo Nordisk A/S
- Novo Nordisk A/S
- Thursday, 01 October 2026
- 12:15 - 12:45 CEST
- Spotlight Stage
Turn Up the Volume or Fine-Tune the Balance? Debating GDMT for cardio-kidney protection
- Bayer AG
- Thursday, 01 October 2026
- 12:15 - 12:45 CEST
- Arena
Hot Topic Session – Roche
- Roche
- Thursday, 01 October 2026
- 15:00 - 15:30 CEST
- Spotlight Stage
Hot Topic Session – Abbott
- Abbott
- Thursday, 01 October 2026
- 17:00 - 17:30 CEST
- Spotlight Stage
Industry symposium – Novo Nordisk A/S
- Novo Nordisk A/S
- Thursday, 01 October 2026
- 18:45 - 20:15 CEST
- Sofia Hall